JP2002500652A - スピロ−キヌクリジン誘導体、その製造方法及びその使用方法 - Google Patents

スピロ−キヌクリジン誘導体、その製造方法及びその使用方法

Info

Publication number
JP2002500652A
JP2002500652A JP50013299A JP50013299A JP2002500652A JP 2002500652 A JP2002500652 A JP 2002500652A JP 50013299 A JP50013299 A JP 50013299A JP 50013299 A JP50013299 A JP 50013299A JP 2002500652 A JP2002500652 A JP 2002500652A
Authority
JP
Japan
Prior art keywords
disease
nicotine
chemical
withdrawal
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP50013299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500652A5 (de
Inventor
ペテルス・ダン
オルセン・グンナル・エム
ニールセン・シモン・フェルトベーク
ニールセン・エルゼベート・エーステルガート
Original Assignee
ニューロサーアチ・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロサーアチ・アクティーゼルスカブ filed Critical ニューロサーアチ・アクティーゼルスカブ
Publication of JP2002500652A publication Critical patent/JP2002500652A/ja
Publication of JP2002500652A5 publication Critical patent/JP2002500652A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP50013299A 1997-05-30 1998-05-29 スピロ−キヌクリジン誘導体、その製造方法及びその使用方法 Withdrawn JP2002500652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0626/97 1997-05-30
DK62697 1997-05-30
PCT/DK1998/000227 WO1998054189A1 (en) 1997-05-30 1998-05-29 Spiro-quinuclidine derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
JP2002500652A true JP2002500652A (ja) 2002-01-08
JP2002500652A5 JP2002500652A5 (de) 2005-12-08

Family

ID=8095721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50013299A Withdrawn JP2002500652A (ja) 1997-05-30 1998-05-29 スピロ−キヌクリジン誘導体、その製造方法及びその使用方法

Country Status (11)

Country Link
US (1) US6352995B1 (de)
EP (1) EP0984970B1 (de)
JP (1) JP2002500652A (de)
CN (1) CN1110499C (de)
AT (1) ATE254618T1 (de)
AU (1) AU744368B2 (de)
CA (1) CA2289578A1 (de)
DE (1) DE69819891T2 (de)
NZ (1) NZ500643A (de)
WO (1) WO1998054189A1 (de)
ZA (1) ZA984637B (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539129A (ja) * 1999-03-05 2002-11-19 サノフィ−サンテラボ ピリドピラノアゼピン誘導体、その製造及びその治療上の適用
JP2006525317A (ja) * 2003-04-29 2006-11-09 ニューリム ファーマシューティカルズ（１９９１）リミテッド 認知および記憶を改善するための組成物
JP2007515483A (ja) * 2003-12-22 2007-06-14 アボット・ラボラトリーズ スピロ環状キヌクリジンエーテル誘導体

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
AU2001284646A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
ES2280538T3 (es) * 2001-06-01 2007-09-16 Astrazeneca Ab Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia.
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
MXPA04004464A (es) 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CN101772346B (zh) 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
EP3801732A4 (de) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Verfahren und systeme zur wirkstofffreisetzung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48452A (en) 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
IL87234A (en) 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
ATE122353T1 (de) 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US4876260A (en) 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5803081A (en) * 1996-06-28 1998-09-08 Regent Court Technologies Tobacco and related products
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539129A (ja) * 1999-03-05 2002-11-19 サノフィ−サンテラボ ピリドピラノアゼピン誘導体、その製造及びその治療上の適用
JP4806123B2 (ja) * 1999-03-05 2011-11-02 サノフィ−アベンティス ピリドピラノアゼピン誘導体、その製造及びその治療上の適用
JP2006525317A (ja) * 2003-04-29 2006-11-09 ニューリム ファーマシューティカルズ（１９９１）リミテッド 認知および記憶を改善するための組成物
JP2012116859A (ja) * 2003-04-29 2012-06-21 Neurim Pharmaceuticals (1991) Ltd 認知および記憶を改善するための組成物
JP2007515483A (ja) * 2003-12-22 2007-06-14 アボット・ラボラトリーズ スピロ環状キヌクリジンエーテル誘導体

Also Published As

Publication number Publication date
CN1257506A (zh) 2000-06-21
AU7426398A (en) 1998-12-30
EP0984970A1 (de) 2000-03-15
DE69819891D1 (de) 2003-12-24
CA2289578A1 (en) 1998-12-03
AU744368B2 (en) 2002-02-21
ATE254618T1 (de) 2003-12-15
ZA984637B (en) 1998-12-21
NZ500643A (en) 2001-12-21
CN1110499C (zh) 2003-06-04
EP0984970B1 (de) 2003-11-19
DE69819891T2 (de) 2004-08-26
US6352995B1 (en) 2002-03-05
WO1998054189A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
JP2002500652A (ja) スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
JP4447663B2 (ja) ニコチン性ａｃｈレセプターに於けるコリン作動性リガンドとしての８−アザビシクロ（３．２．１）オクト−２−エン及びオクタン誘導体
US6392045B1 (en) 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors
JP2003516988A (ja) 新規ヘテロアリール−ジアザビシクロアルカン類
JP2004538268A (ja) Ｃｎｓ−モジュレーターとしての新規ヘテロアリール−ジアザビシクロアルカン類
JP2001522846A (ja) アザ環−エーテル誘導体及びこれをニコチン性ａｃｈレセプターモジュレーターとして使用する方法
JP2002531456A (ja) ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体
JP2002511068A (ja) アザシクロオクタン及びヘプタン誘導体、その製造方法及びこれを用いて治療する方法
JP2001525812A (ja) 神経伝達物質再吸収阻害剤としてのピペリジン誘導体
MXPA05001002A (es) Derivados de diazabiciclononano y decano y su uso como ligandos del receptor opioide.
MXPA00004396A (en) Azaring-ether derivatives and their use as nicotinic ach receptor modulators
MXPA99011081A (en) 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050523

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080121